Sysmex (OTCMKTS:SSMXY) Shares Gap Down – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $12.34, but opened at $11.86. Sysmex shares last traded at $11.88, with a volume of 497 shares.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Sysmex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Sysmex Trading Down 0.6%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The stock has a market capitalization of $7.58 billion, a price-to-earnings ratio of 28.68 and a beta of 1.05. The business has a fifty day simple moving average of $10.19 and a 200 day simple moving average of $9.30.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The company had revenue of $825.85 million during the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, research analysts expect that Sysmex Corporation ADR will post 0.38 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.